Tricyclic drugs for depression in children and adolescents

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 6, 2013, Pages

  Hazell, Philip ^a   Mirzaie, Mohsen ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b SYDNEY LOCAL HEALTH DISTRICT   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CLOMIPRAMINE; DESIPRAMINE; DOSULEPIN; IMIPRAMINE; NORTRIPTYLINE; PLACEBO; PROTRIPTYLINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE;

ADOLESCENT HEALTH; CHECKLIST; CHILD HEALTH; CLINICAL EFFECTIVENESS; DEPRESSION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; META ANALYSIS; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; REMISSION; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREMOR; VERTIGO; XEROSTOMIA; ADOLESCENT; AGE; CHILD; CONFIDENCE INTERVAL; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK;

ADMINISTRATION, ORAL; ADOLESCENT; AGE FACTORS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CHILD; CONFIDENCE INTERVALS; DEPRESSION; HUMANS; ODDS RATIO; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84891708208     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD002317.pub2     Document Type: Review

References (55)

1. Bernstein GA, Garfinkel BD, Borchardt CM. Comparative studies of pharmacotherapy for school refusal. Journal of the American Academy of Child and Adolescent Psychiatry 1990;29:773-81.
2. Bernstein GA, Anderson LK, Hektner JM, Realmuto GM. Imipramine compliance in adolescents. Journal of the American Academy of Child and Adolescent Psychiatry 2000;39(3):284-91.
3. Bernstein GA, Borchardt CM, Perwien AR, Crosby RD, Kushner MG, Thuras PD, et al.Imipramine plus cognitive-behavioural therapy in the treatment of school refusal. Journal of the American Academy of Child and Adolescent Psychiatry 2000;39(3):276-83.
4. Bernstein GA, Hektner JM, Borchardt CM, McMillan MH. Treatment of school refusal: one-year follow-up. Journal of the American Academy of Child & Adolescent Psychiatry 2001;40(2):206-13.
5. Bernstein GA, Warren SL, Massie ED, Thuras PD. Family dimensions in anxious-depressed school refusers. Journal of Anxiety Disorders 1999;13(5):513-28.
6. Layne AE, Bernstein GA, Egan EA, Kushner MG. Predictors of treatment response in anxious-depressed adolescents with school refusal. Journal of the American Academy of Child & Adolescent Psychiatry 2003;42(3):319-26.
7. Birmaher B, Waterman GS, Ryan ND, Perel J, McNabb J, Balach L, et al.Randomized, controlled trial of amitriptyline versus placebo for adolescents with "treatment-resistant" major depression. Journal of the American Academy of Child and Adolescent Psychiatry 1998;37:527-35.
8. Geller B, Cooper TB, Graham DL, Fetner HH, Marsteller FA, Wells JM. Pharmacokinetically designed double-blind placebo-controlled study of nortriptyline in 6-12 year-olds with major depressive disorder. Journal of the American Academy of Child and Adolescent Psychiatry 1992;31:34-44.
9. Geller B, Cooper TB, McCombs HG, Graham D, Wells J. Double-blind, placebo-controlled study of nortriptyline in depressed children using a "fixed plasma level" design. Psychopharmacology Bulletin 1989;25:101-8.
10. Geller B, Cooper TB, Graham DL, Marsteller FA, Bryant DM. Double-blind placebo-controlled study of nortriptyline in depressed adolescents using a "fixed plasma level" design. Psychopharmacology Bulletin 1990;26:85-90.
11. Hughes CW, Preskorn SH, Weller E, Weller R, Hassanein R. Imipramine vs. placebo studies of childhood depression: baseline predictors of response to treatment and factor analysis of presenting symptoms. Psychopharmacology Bulletin 1998;24(2):275-9.
12. Hughes CW, Preskorn SH, Weller E, Weller RA, Hassanein R, Tucker S. The effect of concomitant disorders in childhood depression on predicting treatment response. Psychopharmacology Bulletin 1990;26:235-8.
13. Kashani JH, Shekim WO, Reid JC. Amitriptyline in children with major depressive disorder: a double-blind crossover pilot study. Journal of the American Academy of Child and Adolescent Psychiatry 1984;23:348-51.
14. Keller MB, Ryan ND, Birmaher B, Klein RG, Strober M, Wagner KD, et al.Paroxetine and imipramine in the treatment of adolescent depression. Proceedings of the 151st Annual Meeting of the American Psychiatric Association (APA); 1998 May 30-Jun 4; Toronto, ON, Canada. 1998:123.
15. Keller MB, Ryan ND, Strober M, Klein RG, Kutcher SP, Birmaher B, et al.Efficacy of paroxetine treatment in the treatment of adolescent depression: a randomized, controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry 2001;40(7):762-72.
16. Wagner KD, Birmaher B, Carlson G, Clarke G, Emslie G, Geller B, et al.Safety of paroxetine and imipramine in the treatment of adolescent depression. Annual Meeting of New Clinical Drug Evaluation Program (NCDEU); 1998 Jun 11; Boca Raton (FL). 1998:Abstract No. 69.
17. Klein RG, Mannuzza S, Koplewicz HS, Tancer NK, Shah M, Liang V, et al.Adolescent depression: controlled desipramine treatment and atypical features. Depression & Anxiety 1998;7(1):15-31.
18. Kramer AD, Feguine RJ. Clinical effects of amitriptyline in adolescent depression. Journal of the American Academy of Child and Adolescent Psychiatry 1981;20:636-44.
19. Boulos C, Kutcher S, Marton P, Simeon J, Ferguson B, Roberts N. Response to desipramine treatment in adolescent major depression. Psychopharmacology Bulletin 1991;27:59-65.
20. Kutcher S, Boulos C, Ward B, Marton P, Simeon J, Ferguson HB, et al.Response to desipramine treatment in adolescent depression: a fixed-dose, placebo-controlled trial. Journal of the American Academy of Child & Adolescent Psychiatry 1994;33(5):686-94.
21. Klein RG. Pharmacotherapy of adolescent depression. Pediatric Psychopharmacology 1992;15 Suppl 1, Pt A:227A.
22. Kye CH, Waterman GS, Ryan ND, Birmaher B, Williamson DE, Iyengar S, et al.A randomized, controlled trial of amitriptyline in the acute treatment of adolescent major depression. Journal of the American Academy of Child and Adolescent Psychiatry 1996;35:1139-44.
23. Ryan ND, Puig-Antich J. Affective illness in adolescence. In: Frances AJ, Hales RE editor(s). American Psychiatric Association Annual Review. Vol. 5, Washington, DC: American Psychiatric Press, 1986:420-50.
24. Petti TA, Law W. Imipramine treatment of depressed children: a double-blind pilot study. Journal of Clinical Psychopharmacology 1982;2:107-10.
25. Puig-Antich J, Perel JM, Lupatkin W, Chambers WJ, Tabrizi MA, King J, et al.Imipramine in prepubertal major depressive disorders. Archives of General Psychiatry 1987;44:81-9.
26. Berney T, Kolvin I, Bhate SR, Garside RF, Jeans J, Kay B, et al.School phobia: a therapeutic trial with clomipramine and short-term outcome. British Journal of Psychiatry 1981;138:110-8.
27. Lucas AR, Lockett HJ, Grimm F. Amitriptyline in childhood depressions. Diseases of the Nervous System 1965;26(2):105-10.
28. Preskorn SH, Weller EB, Weller RA. Depression in children: relationship between plasma imipramine levels and response. Journal of Clinical Psychiatry 1982;43:450-3.
29. Sallee FR, Vrindavanam NS, Deas-Smith D, Carson, SW, Sethuraman G. Pulse intravenous clomipramine for depressed adolescents: double-blind, controlled trial. American Journal of Psychiatry 1997;154:668-73.
30. Berard 1998. Clinical trials and tribulations in the pharmacological treatment of adolescent depression. Proceedings of the XXIst Collegium Internationale Neuro Psychopharmacologicum; 1998 Jul 12-16; Glasgow, Scotland. 1998.
31. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association, 2000.
32. Barbey JT, Roose SP. SSRI safety in overdose. Journal of Clinical Psychiatry 1998;59 Suppl:42-8.
33. Birmaher B, Ryan ND, Williamson DE, Brent DA, Kaufman J, Dahl RE, et al.Childhood and adolescent depression: a review of the past 10 years. Part I. Journal of the American Academy of Child and Adolescent Psychiatry 1996;35:1427-39.
34. Byrne MM. Meta-analysis of early phase II studies with paroxetine in hospitalised depressed patients. Acta Psychiatrica Scandinavica, Supplementum 1989;350:138-9.
35. Costello EJ, Foley DL, Angold A. 10-year research update review; the epidemiology of child and adolescent psychiatric disorders: ll. Developmental epidemiology. Journal of American Academy of Child and Adolescent Psychiatry 2006;45(1):8-25.
36. Emslie GJ, Rush R, Weinberg WA, Kowatch WA, Hughes CW, Carmody T, et al.A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Archives of General Psychiatry 1997;54:1031-7.
37. Feighner JP. Mechanism of action of antidepressant medications. Journal of Clinical Psychiatry 1999;60(4):4-11.
38. Hayes BD, Klein-Schwartz W, Clark RF, Muller AA, Miloradovich JE. Comparison of toxicity of acute overdoses with citalopram and escitalopram. Journal of Emergency Medicine 2010;39(1):44-8.
39. Hetrick S, McKenzie J, Cox R, Simmons M, Merry S. Newer generation antidepressants for depressive disorders in children and adolescents. Cochrane Database of Systematic Reviews 2012, Issue 11. [DOI: 10.1002/14651858.CD004851.pub3]
40. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
41. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
42. Jensen PS, Ryan ND, Prien R. Psychopharmacology of child and adolescent major depression: present status and future directions. Journal of Child and Adolescent Psychopharmacology 1992;2:31-45.
43. Klein-Schwartz W, Anderson B. Analysis of sertraline-only overdoses. American Journal of Emergency Medicine 1996;14(5):456-8.
44. McFee RB, Caraccio TR, Mofenson HC. Selected tricyclic antidepressant ingestions involving children 6 years old or less. Academic Emergency Medicine 2001;8(2):139-44.
45. Olgun H, Yildirim ZK, Karacan M, Ceviz N. Clinical, electrocardiographic, and laboratory findings in children with amitriptyline intoxication. Pediatric Emergency Care 2009;25(3):170-3.
46. Petti T. Scales of potential use in the psychopharmacological treatment of depressed children and adolescents. Psychopharmacology Bulletin 1985;21:951-77.
47. Phillips S, Brent J, Kulig K, Heiligenstein J, Birkett M. Fluoxetine versus tricyclic antidepressants: a prospective multicentre study of antidepressant drug overdoses. The Antidepressant Study Group. Journal of Emergency Medicine 1997;15(4):439-45.
48. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
49. Rosenberg ML, Eddy DM, Wolpert RC, Broumas EP. Developing strategies to prevent youth suicide. In: Pfeffer CR editor(s). Suicide Among Youth: Perspectives on Risk and Prevention. Washington, DC: American Psychiatric Press, 1989:203-25.
50. Ryan ND. The pharmacologic treatment of child and adolescent depression. Psychiatric Clinics of North America 1992;15:29-39.
51. Stahl SM. Essential Psychopharmacology. New York: Cambridge University Press, 2006.
52. Varley CK, McClellan J. Case study: two additional sudden deaths with tricyclic antidepressants. Journal of the American Academy of Child & Adolescent Psychiatry 1997;36(3):390-4.
53. Werry JS, Aman MG. Practitioner's Guide to Psychoactive Drugs for Children and Adolescents. New York: Springer, 1999.
54. World Health Organization (WHO). The ICD-10 Classification of Mental and Behavioural Disorders. Geneva: WHO, 1992.
55. Hazell PL, O'Connell D, Heathcote D, Robertson J, Henry D. Efficacy of tricyclic drugs in treating child and adolescent depression: a meta-analysis. BMJ 1995;310:897-901.